Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine

Sheng, Wang‐Huei; Ieong, Si‐Man; Lin, Pin‐Hung; Hsieh, Ming‐Ju; Yang, Hung‐Chih; Pan, Ching‐Fu; Chao, Tai‐Ling; Chang, Shih‐Ying; Chang, Shan-Chwen

doi:10.1016/j.jfma.2022.09.004

Cited by 10 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, some studies evaluated the generation of T-cell responses towards S-derived peptides, demonstrating the presence of S-specific CD4 and CD8 T cells within 10 days to 9 weeks following the first and second dose, or even up to 6 months post-vaccination in healthy donors [ 29 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ]. Furthermore, third and fourth doses led to improved immune responses compared to two doses of mRNA vaccines, leading to a peak in IgG titers in the fourth week postvaccination [ 43 , 44 , 45 ].…”

Section: Advantages and Caveats Of Efficacy And Safety Of Mrna Sars-c...mentioning

confidence: 99%

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

Echaide

Chocarro

Bocanegra

et al. 2023

IJMS

View full text Add to dashboard Cite

The application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection has constituted a determinant resource to control the COVID-19 pandemic. Since the beginning of 2021, millions of doses have been administered in several countries of North and South America and Europe. Many studies have confirmed the efficacy of these vaccines in a wide range of ages and in vulnerable groups of people against COVID-19. Nevertheless, the emergence and selection of new variants have led to a progressive decay in vaccine efficacy. Pfizer–BioNTech and Moderna developed updated bivalent vaccines—Comirnaty and Spikevax—to improve responses against the SARS-CoV-2 Omicron variants. Frequent booster doses with monovalent or bivalent mRNA vaccines, the emergence of some rare but serious adverse events and the activation of T-helper 17 responses suggest the need for improved mRNA vaccine formulations or the use of other types of vaccines. In this review, we discuss the advantages and limitations of mRNA vaccines targeting SARS-CoV-2 focusing on the most recent, related publications.

show abstract

Section: Advantages and Caveats Of Efficacy And Safety Of Mrna Sars-c...mentioning

confidence: 99%

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

Echaide

Chocarro

Bocanegra

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The antibody levels of HD patients were similar to those of healthcare workers (602.00 [307.50-1623.00] U/mL vs 602.50 [391.25-1029.25], p = 0.814). The seroconversion rate among HD patients was 98.96%, whereas that of healthy controls was 100% 21 .…”

Section: Discussionmentioning

confidence: 86%

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in haemodialysis patients: a prospective cohort study

Puspitasari

Sattwika

Rahari

et al. 2023

Sci Rep

View full text Add to dashboard Cite

End-stage renal disease patients on haemodialysis (HD) have been largely excluded from SARS-CoV-2 vaccine trials due to safety reasons and shown to mount lower responses to vaccination. This study aims to evaluate the immunogenicity and safety of inactivated COVID-19 vaccine among HD patients compared to healthy controls. All subjects who received the primary inactivated COVID-19 vaccination had their blood samples tested 21 days after the second dose. We report the immunogenicity based on anti-RBD IgG titre (IU/mL), the inhibition rate of neutralizing antibodies (NAbs) (%) to RBD, and seroconversion rates. Adverse events were assessed within 30 min and on the 7th day after each dose. Among 75 HD patients and 71 healthy controls, we observed no significant difference in all immunogenicity measures: anti-RBD IgG GMT (277.91 ± 7.13 IU/mL vs. 315.50 ± 3.50 IU/mL, p = 0.645), NAbs inhibition rate (82% [53–96] vs. 84% [39–98], p = 0.654), and seroconversion rates (anti-RBD IgG: 86.7% vs. 85.9%, p = 0.895; NAbs: 45.3% vs. 60.6%, p = 0.065). The number of adverse events is not significantly different between the two groups. The primary inactivated SARS-CoV-2 vaccination elicits an adequate antibody response and can be safely administered in haemodialysis patients.

show abstract

“…Sheng et al. 5 thus investigated the immunogenicity and adverse events of the third dose of mRNA COVID-19 vaccines in healthy adults vaccinated with two doses of the adenoviral vaccine (ChAdOx1) 12 weeks before. They were divided into three groups, full-dose mRNA-1273 (group 1); half-dose mRNA-1273 (group 2); and full-dose BNT-162b2 (group 3).…”

Section: Immunogenicity and Safety Of Third-dose Mrna Covid-19 Vaccin...mentioning

confidence: 99%

Highlights

Kao¹

2023

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine

Cited by 10 publications

References 22 publications

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in haemodialysis patients: a prospective cohort study

Highlights

Contact Info

Product

Resources

About